CU20130149A7 - COMPOUNDS OF 2- (2,4,5-REPLACED ANILINO) PYRIMIDINE - Google Patents
COMPOUNDS OF 2- (2,4,5-REPLACED ANILINO) PYRIMIDINEInfo
- Publication number
- CU20130149A7 CU20130149A7 CU2013000149A CU20130149A CU20130149A7 CU 20130149 A7 CU20130149 A7 CU 20130149A7 CU 2013000149 A CU2013000149 A CU 2013000149A CU 20130149 A CU20130149 A CU 20130149A CU 20130149 A7 CU20130149 A7 CU 20130149A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- salts
- pyrimidine
- useful
- mutant
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical class [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a ciertos compuestos de 2-(2,4,5-anilino sustituido) pirimidina y sales farmacéuticamente aceptables de los mismos que pueden ser útiles en el tratamiento o prevención de una enfermedad o afección mediada por ciertas formas mutadas de receptor del factor de crecimiento epidérmico ( por ejemplo el mutante activo L858R, el mutante activante de la supresión Exon19 y el mutante de resistencia T790M). Tales compuestos y sales de los mismos pueden ser útiles en el tratamiento o prevención de un número de diferentes cánceres. La invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos y sales de los mismos, especialmente formas polimórficas útiles de estos compuestos y sales.The present invention relates to certain 2- (2,4,5-substituted anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof that may be useful in the treatment or prevention of a disease or condition mediated by certain mutated forms of receptor of the epidermal growth factor (for example the active mutant L858R, the activating mutant of the Exon19 suppression and the resistance mutant T790M). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591363P | 2012-01-27 | 2012-01-27 | |
| PCT/GB2012/051783 WO2013014448A1 (en) | 2011-07-27 | 2012-07-25 | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20130149A7 true CU20130149A7 (en) | 2014-04-24 |
Family
ID=52394772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2013000149A CU20130149A7 (en) | 2012-01-27 | 2013-11-14 | COMPOUNDS OF 2- (2,4,5-REPLACED ANILINO) PYRIMIDINE |
Country Status (2)
| Country | Link |
|---|---|
| CU (1) | CU20130149A7 (en) |
| EA (2) | EA036521B1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10237722A1 (en) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indole or benzimidazole derivatives for the modulation of IKappaB kinase |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| US8450335B2 (en) * | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| KR101256018B1 (en) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase |
-
2012
- 2012-07-25 EA EA201990482A patent/EA036521B1/en not_active IP Right Cessation
- 2012-07-25 EA EA202092034A patent/EA202092034A3/en unknown
-
2013
- 2013-11-14 CU CU2013000149A patent/CU20130149A7/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202092034A2 (en) | 2020-12-30 |
| EA201990482A1 (en) | 2019-07-31 |
| EA036521B1 (en) | 2020-11-19 |
| EA202092034A3 (en) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013033A (en) | DERIVATIVES OF 2- (2,4,5-REPLACED ANILINO) PYRIMIDINE AS EGFR MODULATORS USED FOR CANCER TREATMENT | |
| CU20160109A7 (en) | INDAZOL COMPOUNDS AS IRAK4 INHIBITORS | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| MX379110B (en) | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS. | |
| MX2016009013A (en) | BICYCLIC HETEROCICLYL DERIVATIVES AS INHIBITORS OF CINASA-4 ASSOCIATED WITH THE INTERLEUCINE-1 RECEIVER (IRAK4). | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| PH12016501355B1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| MX2020010674A (en) | Muscarinic receptor agonists. | |
| UY34530A (en) | ANTAGONISTS OF THE TRANSITORY POTENTIAL VANILLOID RECEIVER 1 (TRPV1) | |
| CO6491060A2 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES | |
| NI201400134A (en) | NOVELTY N - PYRIDINIL CYCLIC AMIDES REPLACED AS KINASE INHIBITORS. | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| CL2016002267A1 (en) | Asymmetric p-substituted areas and medical uses thereof | |
| CY1123185T1 (en) | INDOLE DERIVATIVES | |
| MA39450A1 (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
| CU20130149A7 (en) | COMPOUNDS OF 2- (2,4,5-REPLACED ANILINO) PYRIMIDINE | |
| MX378175B (en) | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN BOTH MEDICINE AND COSMETICS. | |
| UA108954C2 (en) | Compounds 2- (2,4,5-substituted aniline) pyrimidine | |
| CU20140134A7 (en) | NOVEDOSAS N-PIRIDINIL CYCLIC AMIDAS REPLACED AS QUINASE INHIBITORS |